Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Positron has a long history in cardiac molecular imaging, with its Attrius® cardiac PET system commercially available. The company’s new Affinity™ PET–CT device began clinical studies in September 2023 at Ochsner Clinic Foundation to support FDA clearance. In June 2024, Positron entered an agreement to acquire the FDA-cleared NeuSight™ PET–CT from Neusoft Medical Systems’ subsidiary, expanding its product line into both cardiac and oncology molecular imaging. Results from ongoing clinical studies will determine the commercial launch of these next-generation devices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Positron.